Literature DB >> 3780830

Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.

G Mikus, H R Ha, S Vozeh, C Zekorn, F Follath, M Eichelbaum.   

Abstract

The pharmacokinetics and metabolism of quinidine were investigated in extensive and poor metabolisers of sparteine. No differences in plasma clearance, terminal half life, volume of distribution or cumulative urinary excretion of quinidine, 3-hydroxyquinidine and quinidine-N-oxide were observed between phenotypes. Thus, it is unlikely that quinidine metabolism is controlled by the sparteine/debrisoquine gene locus.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3780830     DOI： 10.1007/bf00870989

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  11 in total

1.  Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.

Authors:  M S Lennard; J H Silas; S Freestone; J Trevethick
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

2.  A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.

Authors:  T Inaba; M Nakano; S V Otton; W A Mahon; W Kalow
Journal:  Can J Physiol Pharmacol       Date:  1984-07       Impact factor: 2.273

Review 3.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

4.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

5.  Specific determination of quinidine and metabolites in biological fluids by reversed-phase high-performance liquid chromatography.

Authors:  R Leroyer; C Jarreau; M Pays
Journal:  J Chromatogr       Date:  1982-03-12

6.  Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation.

Authors:  C Zekorn; G Achtert; H J Hausleiter; C H Moon; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1985-11-15

7.  Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.

Authors:  P Dayer; L Balant; A Kupfer; R Striberni; T Leemann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Influence of the defective metabolism of sparteine on its pharmacokinetics.

Authors:  M Eichelbaum; N Spannbrucker; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  Polymorphic drug oxidation in humans.

Authors:  M Eichelbaum
Journal:  Fed Proc       Date:  1984-05-15

10.  Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.

Authors:  A R Boobis; S Murray; C E Hampden; D S Davies
Journal:  Biochem Pharmacol       Date:  1985-01-01       Impact factor: 5.858
View more
  18 in total

Review 1.  Systems dynamics in clinical pharmacokinetics. An introduction.

Authors:  J M van Rossum; J E de Bie
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

2.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

4.  Substantial rise in sparteine metabolic ratio during haloperidol treatment.

Authors:  L F Gram; D Debruyne; V Caillard; J P Boulenger; J Lacotte; M Moulin; E Zarifian
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

5.  Debrisoquine oxidation phenotype during neuroleptic monotherapy.

Authors:  E Spina; C Martines; A P Caputi; J Cobaleda; B Piñas; J A Carrillo; J Benitez
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

7.  Interindividual variability in the N-sulphation of desipramine in human liver and platelets.

Authors:  P Romiti; L Giuliani; G M Pacifici
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

8.  Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol.

Authors:  T D Leemann; K P Devi; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.

Authors:  N Feifel; K Kucher; L Fuchs; M Jedrychowski; E Schmidt; K H Antonin; P R Bieck; C H Gleiter
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.

Authors:  S Wanwimolruk; S Chalcroft
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.